Cargando…

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

BACKGROUND: Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). Everolimus acts synergistically with eribulin in TNBC cell lines and xenograft models. This phase I trial was designed to test the safety and tolerability of combinin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jin Sun, Yost, Susan E., Blanchard, Suzette, Schmolze, Daniel, Yin, Hongwei Holly, Pillai, Raju, Robinson, Kim, Tang, Aileen, Martinez, Norma, Portnow, Jana, Wen, Wei, Yim, John H., Brauer, Heather Ann, Ren, Yuqi, Luu, Thehang, Mortimer, Joanne, Yuan, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839083/ https://www.ncbi.nlm.nih.gov/pubmed/31703728 http://dx.doi.org/10.1186/s13058-019-1202-4

Ejemplares similares

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
por: Wen, Wei, et al.
Publicado: (2019)

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival
por: Afkhami, Michelle, et al.
Publicado: (2019)

Differential gene expression and AKT targeting in triple negative breast cancer
por: Lin, Feng-Mao, et al.
Publicado: (2019)

Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
por: Yuan, Yuan, et al.
Publicado: (2019)

Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis
por: He, Ting-Fang, et al.
Publicado: (2020)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer
por: Lavasani, Sayeh M., et al.
Publicado: (2022)

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
por: Egelston, Colt A., et al.
Publicado: (2023)

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
por: Rao, Shreyas S., et al.
Publicado: (2017)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
por: Xie, Xuemei, et al.
Publicado: (2023)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2019)

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
por: Pederson, Petra J., et al.
Publicado: (2021)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts
por: Mercatali, Laura, et al.
Publicado: (2016)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models
por: Takahashi-Ruiz, Leila, et al.
Publicado: (2022)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
por: Yuan, Peng, et al.
Publicado: (2021)

Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome
por: Wortman, Juliana C., et al.
Publicado: (2021)

Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity
por: Ding, Yuan Chun, et al.
Publicado: (2019)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus
por: Arora, Shalabh, et al.
Publicado: (2016)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

An α-chloroaldehyde-based formal synthesis of eribulin
por: Kaghad, Anissa, et al.
Publicado: (2023)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
por: Lee, Jin Sun, et al.
Publicado: (2020)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus
por: Geng, Wenwen, et al.
Publicado: (2023)

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
por: Shimomura, Akihiko, et al.
Publicado: (2019)

Third Line Eribulin for Triple-negative Metastatic Breast Ductal Carcinoma Resulting in Extended Progression-free Survival of 57 Months
por: Manthri, Sukesh, et al.
Publicado: (2020)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022)

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
por: Kazmi, Shayma, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bqcc9mlht8dq1g5isc948647q1